Key Takeaways
- • Arboretum LifeSciences closed $30 million in Series A funding led by F-Prime Capital, with participation from GV, .406 Ventures, Hims & Hers, Amgen, and other industry investors, to expand genetic testing for common diseases beyond oncology.
- • The Cambridge-based precision medicine company, founded by data scientists from the Broad Institute, integrates AI-powered genetic testing with clinical care to identify genetically-defined patient populations for both better treatment outcomes and genomically-stratified clinical trials.
- • Arboretum's current healthcare delivery partners include Advocate Health, Cardiovascular Associates of America, Geisinger Health, and Providence Healthcare, positioning the company to scale access to molecular information across major health systems.
- • The company targets common diseases including coronary artery disease, diabetes, and neurodegeneration—areas historically underserved by precision medicine compared to oncology—with the goal of enabling drug developers to identify patient subpopulations most likely to benefit from targeted therapies.
- • CEO Anthony Philippakis frames Arboretum's thesis as extending the molecular stratification model that transformed oncology two decades ago into broader therapeutic categories where genetic information can drive superior clinical outcomes.
Summary
Arboretum LifeSciences launched with $30 million in Series A funding to establish precision medicine infrastructure for common diseases, marking a strategic expansion of genetic testing beyond oncology applications. Founded by leaders in data science from the Broad Institute, the Cambridge-based company combines AI-driven analysis with clinical genetic testing to create genomically-informed patient populations for both improved patient outcomes and clinical trial recruitment.
The funding round, led by F-Prime Capital with participation from prominent investors including GV, .406 Ventures, Hims & Hers, and Amgen, reflects industry confidence in applying molecular stratification to therapeutic areas historically treated as monolithic patient populations. The company has already established partnerships with major health systems including Advocate Health, Cardiovascular Associates of America, Geisinger Health, and Providence Healthcare, providing operational infrastructure to deliver genetic testing at scale.
According to CEO Anthony Philippakis, Arboretum targets conditions including coronary artery disease, diabetes, and neurodegeneration—diseases where genetic variation significantly influences treatment response but remain largely unaddressed by precision medicine approaches. The company's thesis mirrors oncology's transformation two decades ago, when molecular profiling shifted focus from treating all patients uniformly to identifying genetically-defined subpopulations with superior outcomes to targeted therapies. By building the scientific and operational infrastructure to extend this model to common diseases, Arboretum aims to simultaneously improve patient care and solve a critical drug development challenge: identifying populations most likely to benefit from specific therapeutics, thereby increasing clinical trial success rates and enabling more efficient therapeutic development.
The funding round, led by F-Prime Capital with participation from prominent investors including GV, .406 Ventures, Hims & Hers, and Amgen, reflects industry confidence in applying molecular stratification to therapeutic areas historically treated as monolithic patient populations. The company has already established partnerships with major health systems including Advocate Health, Cardiovascular Associates of America, Geisinger Health, and Providence Healthcare, providing operational infrastructure to deliver genetic testing at scale.
According to CEO Anthony Philippakis, Arboretum targets conditions including coronary artery disease, diabetes, and neurodegeneration—diseases where genetic variation significantly influences treatment response but remain largely unaddressed by precision medicine approaches. The company's thesis mirrors oncology's transformation two decades ago, when molecular profiling shifted focus from treating all patients uniformly to identifying genetically-defined subpopulations with superior outcomes to targeted therapies. By building the scientific and operational infrastructure to extend this model to common diseases, Arboretum aims to simultaneously improve patient care and solve a critical drug development challenge: identifying populations most likely to benefit from specific therapeutics, thereby increasing clinical trial success rates and enabling more efficient therapeutic development.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.